Cancer drug pollution is a growing global concern 
Why banks consider renewable energy to be a riskier investment than fossil fuels 
Skechers Sales Surge as Growth Lags for Nike and Adidas; Nike Eyes 2024 Olympics 
McDonald’s Rolls Out $5 Meal Deals to Emphasize Affordability Amid Rising Costs 
Aldi, Hy-Vee Recall Cream Cheese Products Over Potential Salmonella Contamination 
Tesla Scrambles to Soothe European Backlash Over Fleet Price Cuts, Maintenance Costs 
Semaglutide's Benefits Beyond Weight Loss: New Insights from the SELECT Trial 
Tesla Cybertruck Trails Ford F-150 Lightning in Sales as Q1 Figures Disappoint Wall Street 
Shanghai's Data Policy Shift Could Propel Tesla's Local Data Center Efforts 
Burger King’s Largest Franchisee Carrols, Acquired by RBI for $1 Billion, $500M Revamp 
FC Barcelona Negotiates New Nike Deal, Plans Loan Amid Financial Uncertainty 
Shein's Potential London IPO Could Revitalize LSE Amid Geopolitical Tensions 
Skepta Says Puma Is 'Much Better Deal' Than Nike, Reveals New Sneaker Collaboration 
CAMBRIDGE, Mass., Feb. 09, 2017 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, February 16, 2017 at 8:00 a.m. ET to report its fourth quarter and full year 2016 financial results and discuss recent clinical development and corporate activities.
The live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. The conference call can be accessed by dialing 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and refer to conference ID 61135222. The webcast will be archived and made available for replay on the company's website beginning approximately two hours after the event.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company's website at www.agios.com.
Agios Pharmaceuticals: Kendra Adams, 617-844-6407 Senior Director, Investor & Public Relations [email protected] Renee Leck, 617-649-8299 Senior Manager, Investor & Public Relations [email protected]
